|
Note
7 – Accrued Expenses and Other Liabilities
Accrued
expenses and other liabilities, summarized by major category, consist of the following for years ended December 31, 2023 and 2022:
Schedule of Accrued Expenses
| |
|
2023 |
|
|
2022 |
|
| |
|
As of December 31, |
|
| |
|
2023 |
|
|
2022 |
|
| Payroll and incentives |
|
$ |
1,176 |
|
|
$ |
1,705 |
|
| General and administrative expenses |
|
|
196 |
|
|
|
455 |
|
| Research and development expenses |
|
|
75 |
|
|
|
130 |
|
| Deferred revenue * |
|
|
— |
|
|
|
721 |
|
| Other deferred liabilities ** |
|
|
— |
|
|
|
88 |
|
| Total |
|
$ |
1,447 |
|
|
$ |
3,099 |
|
| * |
At
December 31, 2022, the balance included $688 related to an exclusive research collaboration with BioNTech SE (the “BioNTech
Agreement”) and $33 is related to a feasibility study agreement with Genentech, Inc. (the “Genentech Agreement”).
(See Note 9 – Revenue Recognition, Collaboration Agreements, and Other research and Development Agreements). |
| ** |
At
December 31, 2022, the balance of $88 was related to an award agreement with the Cystic Fibrosis Foundation (the “CFF Agreement).
(See Note 9 – Revenue Recognition, Collaboration Agreements, and Other Research and Development Agreements). |
|